Combination Therapy for Premature Ejaculation

The patent replaces the mechanical/behavioral intervention system of psychotherapy with a pharmacological system. Instead of requiring specialized therapists to deliver behavioral therapy, the invention uses chemical compounds (antidepressants, topical anesthetics, or their combinations) to achieve the therapeutic effect of delaying ejaculation, thereby eliminating the need for specialized therapeutic intervention and improving patient convenience.

The patent changes the chemical parameters of the treatment by using different classes of compounds (antidepressants like SSRIs, or topical anesthetics like lidocaine) with varying mechanisms of action and side effect profiles. By selecting compounds with appropriate potency and specificity, the invention aims to achieve the desired duration extension while minimizing harmful side effects through parameter optimization rather than using a single fixed treatment approach.

The patent employs parameter changes by using different antidepressant compounds (SSRIs, SNRIs, TCAs) with varying pharmacological properties, dosages, and side effect profiles. The invention optimizes treatment by selecting specific compounds and dosages to achieve the desired delay in ejaculation while minimizing adverse effects through careful parameter adjustment rather than uniform treatment protocols.

The patent merges multiple pharmacological agents (μ-opiate analgesics like tramadol, NMDA receptor antagonists like dextromethorphan, and phosphodiesterase type 5 inhibitors like sildenafil) into a single combination therapy. This merging approach addresses different physiological mechanisms simultaneously - pain modulation, excitatory neurotransmission blockade, and vascular function enhancement - thereby improving overall treatment effectiveness while potentially reducing the need for multiple separate treatments.